Cardio Diagnostics Holdings Inc.
CDIOCardio Diagnostics is a medical technology company that develops and commercializes AI-driven multi-omics solutions for the prevention, early detection, and management of cardiovascular disease.
Table of contents
Earnings
Next report
Aug 13, 2026 (in a month)Competitors
By market cap
By revenue growth
Profile
Cardio Diagnostics is a medical technology company that develops and commercializes AI-driven multi-omics solutions for the prevention, early detection, and management of cardiovascular disease. By integrating genetic and epigenetic biomarkers through a proprietary machine learning engine, the company provides clinical tests that assess near-term risk for heart attacks and detect coronary heart disease. Their platform aims to transform cardiovascular care from reactive treatment to proactive precision medicine for patients, clinicians, and employers.
The company is a pioneer in epigenetics-based cardiovascular diagnostics, offering tests with significantly higher sensitivity for near-term heart attack risk than traditional standards like the Framingham Risk Score.
Questions, answered.
- What is Cardio Diagnostics Holdings Inc.'s market cap?
- Cardio Diagnostics Holdings Inc. (CDIO) has a market capitalization of $5.5M and trades on NASDAQ.
- Who are Cardio Diagnostics Holdings Inc.'s competitors?
- Cardio Diagnostics Holdings Inc.'s key competitors include Zepp Health (Huami), Grail, Biodesix, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Cardio Diagnostics Holdings Inc. partner with?
- Cardio Diagnostics Holdings Inc.'s notable partners include University of Iowa Research Foundation, Intermountain Healthcare, YMCA of East Tennessee, and others.
- Where is Cardio Diagnostics Holdings Inc. headquartered?
- Cardio Diagnostics Holdings Inc. is headquartered in United States of America and employs approximately 9 people. It has been publicly traded since 2022.